Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
Preschoolers are likely to follow an unhealthy dietary pattern, and patterns high in processed food and snacks contribute to an increased risk of attention-deficit/hyperactivity disorder (ADHD), whereas a pattern high in vegetables exerts a protective effect, according to a study from China.
Individuals with attention-deficit hyperactivity disorder (ADHD) who are treated with atomoxetine or methylphenidate may have a risk for elevated heart rate and systolic blood pressure (BP), according to a meta-analysis.
Individuals with attention deficiency hyperactivity disorder (ADHD) or anxiety are at greater risk of developing bipolar disorder, according to a study. Moreover, the risk further increases in those who have received diagnoses of both ADHD and anxiety.
A substantial number of patients with gambling addiction screen positive for attention-deficit/hyperactivity disorder (ADHD), according to a Singapore study. Furthermore, these patients have lower levels of gambling-related cognitions, suggesting that their gambling behaviour is rather guided by impulsivity.
Youths treated with a 12-week course of either olanzapine, risperidone, or aripiprazole may have an increased risk for elevated adiposity and decreased insulin sensitivity, according to a recent study.
Neither multinutrient supplementation nor food-related behavioural activation therapy appear to protect against major depressive disorder (MDD) episodes in overweight or obese adults with subsyndromal depressive symptoms, according to a recent study.
Cannabis use disorder appears to exert a beneficial effect on the risk of disorders of gut–brain interaction and inflammatory bowel disease in patients with schizophrenia but not in population controls, a study has found. This finding raises the possibility of new targets for treatment and prevention of digestive organ disorders in schizophrenia.